Abstract:Our previous studies led us to conclude that thiophene[3,2-d]pyrimidine is a promising scaffold for diarylpyrimidine (DAPY)-type anti-HIV agents with potent activity against resistance-associated human immunodeficiency virus (HIV) variants (J. Med. Chem. 2016, 59, 7991-8007; J. Med. Chem. 2017, 60, 4424-4443). In the present study, we designed and synthesized a series of thiophenepyrimidine derivatives with various substituents in the right wing region of the structure with the aim of developing new interactions with the tolerant region I of the binding pocket of the HIV-1 non-nucleoside reverse transcriptase (NNRTI), and we evaluated their activity against a panel of mutant HIV-1 strains. All the derivatives exhibited moderate to excellent potency against wild-type (WT) HIV-1 in MT-4 cells. Among them, sulfonamide compounds 9b and 9d were single-figure-nanomolar inhibitors with EC50 values of 9.2 and 7.1 nM, respectively. Indeed, 9a and 9d were effective against the whole viral panel except RES056. Notably, both compounds showed potent antiviral activity against K103N (EC50 = 0.032 and 0.070 μM) and E138K (EC50 = 0.035 and 0.045 μM, respectively). Furthermore, 9a and 9d exhibited high affinity for WT HIV-1 RT (IC50 = 1.041 and 1.138 μM, respectively) and acted as classical NNRT inhibitors (NNRTIs). These results are expected to be helpful in the design of thiophenepyrimidine-based NNRTIs with more potent activity against HIV strains with RT mutations.

Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.

Structural Optimization of Pyridine-Type DAPY Derivatives to Exploit the Tolerant Regions of the NNRTI Binding Pocket.

Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.

Structure-based discovery of novel piperidine-biphenyl-DAPY derivatives as non-nucleoside reverse transcriptase inhibitors featuring improved potency, safety, and selectivity: From piperazine-biphenyl-DAPYs to piperidine-biphenyl-DAPYs

Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.

Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.

Design, synthesis, and antiviral evaluation of novel piperidine-substituted arylpyrimidines as HIV-1 NNRTIs by exploring the hydrophobic channel of NNIBP

Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.

Identification of Dihydrofuro[3,4- D]pyrimidine Derivatives As Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.

Design, Synthesis, and Sar of Naphthyl-Substituted Diarylpyrimidines As Non-Nucleoside Inhibitors of Hiv-1 Reverse Transcriptase

Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach

Exploiting the Tolerant Region I of Non-nucleoside Reverse Transcriptase Inhibitor Binding Pocket (NNIBP): Discovery of Potent Diarylpyrimidine (DAPY)-typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.

Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses

Chemical space exploration of novel naphthyl-carboxamide-diarylpyrimidine derivatives with potent anti-HIV-1 activity

Discovery of Thiophene[3,2-d]pyrimidine Derivatives As Potent HIV-1 NNRTIs Targeting the Tolerant Region I of NNIBP.

Structure-guided Design of Novel Biphenyl-Quinazoline Derivatives As Potent Non-Nucleoside Reverse Transcriptase Inhibitors Featuring Improved Anti-Resistance, Selectivity, and Solubility

Structural Modification of Diarylpyrimidine Derivatives As HIV-1 Reverse Transcriptase Inhibitors

Identification of "Dual-Site"-binding Diarylpyrimidines Targeting Both NNIBP and the NNRTI Adjacent Site of the HIV-1 Reverse Transcriptase.

Exploring the Hydrophobic Channel of NNIBP Leads to the Discovery of Novel Piperidine-Substituted Thiophene[3,2-D]pyrimidine Derivatives As Potent HIV-1 NNRTIs

Fragment Hopping-Based Discovery of Novel Sulfinylacetamide-Diarylpyrimidines (dapys) As HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors

Design, Synthesis and Anti-Hiv Evaluation of Novel Diarylpyridine Derivatives As Potent HIV-1 NNRTIs.